Decitabine

For research use only.

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine

81 publications

Decitabine Chemical Structure

CAS No. 2353-33-5

Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 152 In stock
EUR 88 In stock
EUR 167 In stock
EUR 314 In stock
EUR 560 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Decitabine has been cited by 81 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M3XLUGZ2dmO2aX;uJGF{e2G7 MkPpNE42yqEQvF2= NELycIIzPCCq NYfu[Yd5f2G2ZYK= NGSyOWtud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? M1XmUFI2OTJ|MEiy
Eca109 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDpeWsxNjVxMj61M|Uh|ryP NGrTXVEzPC92OD:3NkBp NUCxdGgyf2G2ZYK= M4jobolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NXHxN4JLOjVzMkOwPFI>
Eca109 NWTkVlZwTnWwY4Tpc44hSXO|YYm= MYGwMlXDqM7:TR?= M4\wclYwOTJxMkSgbC=> M17ET5difGW{ NEnBW|lqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg NWSwfHloOjVzMkOwPFI>
Eca109 NFvR[25HfW6ldHnvckBCe3OjeR?= NHTTdIcxNjYEoN88US=> M4DyPFI1KGh? NX;vS|duf2G2ZYK= M3zUOIlvcGmkaYTzJINmdGxiaX72ZZNqd25? MV2yOVEzOzB6Mh?=
Eca109 NFfZW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmwMlXDqM7:TR?= MWSyOEBp MmXTe4F1\XJ? Ml;RbY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> MUKyOVEzOzB6Mh?=
Eca109 NVHOXHE4TnWwY4Tpc44hSXO|YYm= M3u1eFAvPS9zIN88US=> M3PldFI1KGh? NGfOWnl4[XSnch?= M3rOd4Rm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ? NVfZd5hbOjVzMkOwPFI>
SW1116  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6wMlUwOS9{L{Wg{txO NFT4cVg1QCCq MmG0SG1UVw>? NWq3VYxi\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? MYSyOFg4PDJ6Nh?=
LOVO NF24S3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fmTFAvPS9zL{KvOUDPxE1? MXy0PEBp NHeweYtFVVOR NWDBN2lb\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? MkXiNlQ5PzR{OE[=
SW1116  NUnvN4Q3TnWwY4Tpc44hSXO|YYm= M3v4TlExKM7:TR?= MoHKOFghcA>? NHnRO3JFVVOR NIXNTplqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? MVuyOFg4PDJ6Nh?=
LOVO Ml;3SpVv[3Srb36gRZN{[Xl? MVuxNEDPxE1? M2jj[|Q5KGh? Mo\oSG1UVw>? M2jUfolv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MXOyOFg4PDJ6Nh?=
SW1116  NV7lb|NiSXCxcITvd4l{KEG|c3H5 NE\xSXIyOCEQvF2= M4DVfVQ5KGh? MVfEUXNQ MkK1[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz NEP0UpEzPDh5NEK4Oi=>
LOVO NHrCO2xCeG:ydH;zbZMhSXO|YYm= M2\zcVExKM7:TR?= NVHtXZV{PDhiaB?= NGi2Z|ZFVVOR MVnlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= MoTtNlQ5PzR{OE[=
RPMI-8226 NIWzSpFCeG:ydH;zbZMhSXO|YYm= MmPoNU8zKM7:TR?= MVS0PE84Oi97NjDo NXi1TlhMTE2VTx?= NFnJbo1qdmS3Y3XzJINmdGxiYYDvdJRwe2m| MlG0NlQ5OzNzMEi=
OPM-2  NXXoPIFxSXCxcITvd4l{KEG|c3H5 NFS5eHcyNzJizszN NXfFUlZzPzJxOU[vNVIxKGh? M3jwNGROW09? MY\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MkntNlQ5OzNzMEi=
JJN3  Ml\RRZBweHSxc3nzJGF{e2G7 NHvsNYgxNjVxMTFOwG0> MVKyOE81QCCq MXPEUXNQ Ml\3bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MkD4NlQ5OzNzMEi=
NCI-H929  M4O2emFxd3C2b4Ppd{BCe3OjeR?= MljqNU8zKM7:TR?= MoHMO|IwQTZxMUKwJIg> MUTEUXNQ MonxbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NIDkeG0zPDh|M{GwPC=>
RPMI-8226 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPvNU8zKM7:TR?= M1jkbFI1NzR6L{eyJIg> NI\weGVFVVOR M3ju[4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 M{nTSlI1QDN|MUC4
OPM-2  NX;mR4xtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKxM|Ih|ryP MYWyOE81QC95MjDo NEP2[m1FVVOR MofWZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MlTSNlQ5OzNzMEi=
JJN3  NIC1NG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfCd5pzOC53L{Gg{txO MnewNlQwPDhxN{KgbC=> MmHSSG1UVw>? NVPBRmJE[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NXf5U4gyOjR6M{OxNFg>
NCI-H929  Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH6NU8zKM7:TR?= NFfWRWIzPC92OD:3NkBp NIfIeFRFVVOR M3zTVoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MnzwNlQ5OzNzMEi=
HeLa NUf5OopoU2mwYYPlJGF{e2G7 M4nxUGtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE> MXSyOFc5ODB7OB?=
HeLa Ml;xT4lv[XOnIFHzd4F6 NWLBZlFnU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz M1;5VVI1PzhyMEm4
HeLa M4fyPGtqdmG|ZTDBd5NigQ>? M1XGZmtqRTJzLk[gxtEhOy5yIN88UUBnd3JiaFPOWFE> M{XDSlI1PzhyMEm4
HeLa MnH4T4lv[XOnIFHzd4F6 MUHLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz NYmzVWliOjR5OECwPVg>
NB4 M3v5d2Z2dmO2aX;uJGF{e2G7 M1XzV|IvPS93L{euOU8yOCEQvF2= NUHtPZhFOjRiaB?= Mne1SG1UVw>? MoSxbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=> M3PmVlI1PDh2OEew
CD4+ CD25− T  NHPkZWpHfW6ldHnvckBCe3OjeR?= MXOxM|Uh|ryP NF[0ZXZz\WS3Y3XTJIdtd2KjbDDEUmEhdWW2aInsZZRqd25? MnLNNlQ1PzZ|NkC=
BV-173 Mn\KRZBweHSxc3nzJGF{e2G7 MWmwMlI2NzBwNT:wMlc2NzFizszN NUHIVlRUPDhxN{KvPVYhcA>? MVZCpHBDWw>? MYTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M3\QTlI1PDJ|NkGz
ML-1 M17vZ2Fxd3C2b4Ppd{BCe3OjeR?= M1ThV|AvOjVxMD61M|AvPzVxMTFOwG0> NYrXXJlKPDhxN{KvPVYhcA>? MkS3xsBRSlN? NIXBUmhqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NFXhXYszPDR{M{[xNy=>
HL-60 MlrKRZBweHSxc3nzJGF{e2G7 MVewMlI2NzBwNT:wMlc2NzFizszN M{OzOlQ5Nzd{L{m2JIg> NFnoSmbDqFCEUx?= MWDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NHnyTIYzPDR{M{[xNy=>
KG-1a M1K1VWFxd3C2b4Ppd{BCe3OjeR?= M4\Xc|AvOjVxMD61M|AvPzVxMTFOwG0> NWOyTo9LPDhxN{KvPVYhcA>? NE\wTozDqFCEUx?= NEnuPWxqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MXqyOFQzOzZzMx?=
BV-173 MnTJSpVv[3Srb36gRZN{[Xl? NX3aXWF{OjVyL{WwNI5O Mnq5OFghcA>? NHjUe3rDqFCEUx?= NGq5bY9qdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NWPuRZM2OjR2MkO2NVM>
CEM MlfvSpVv[3Srb36gRZN{[Xl? NV7lT|l4OjVyL{WwNI5O NX\uNm03PDhiaB?= NYO3TZhTyqCSQmO= MkXxbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MlnRNlQ1OjN4MUO=
HL-60 MoXhSpVv[3Srb36gRZN{[Xl? NInic5gzPTBxNUCwcm0> MmTNOFghcA>? Mn7kxsBRSlN? NVu4OmdxcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MVmyOFQzOzZzMx?=
ML-1 M{XGWWZ2dmO2aX;uJGF{e2G7 MXKyOVAwPTBybl2= Ml3sOFghcA>? Mn\ZxsBRSlN? NF7LXm5qdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NHy3SXYzPDR{M{[xNy=>
DLD-1 MWjGeY5kfGmxbjDBd5NigQ>? MUWyOVAwPTBybl2= MmXZOFghcA>? MX5CpHBDWw>? MnrF[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? MnHSNlQ1OjN4MUO=
HCT-116 NVPvUnJRTnWwY4Tpc44hSXO|YYm= MXGyOVAwPTBybl2= MX:0PEBp MVxCpHBDWw>? M3fyZoRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M2LWUlI1PDJ|NkGz
U937-A/E-9/14/18  NV\GN4dOSXCxcITvd4l{KEG|c3H5 MYewMlAyNzBwMT:xM|ExKM7:TR?= M3y4[VQ5KGh? Mme5bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYWyOFMxODR3Nh?=
HT29 M{HwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nMUFczKGh? NFPxeIhKSzVyPUG0NFDDuTF5OTFOwG0> MlrLNlQyPzJyNkG=
SW48 M{\ZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HvdFczKGh? NWrBO|g4UUN3ME2xOU4zyrF4LkKg{txO NWHvfYNGOjRzN{KwOlE>
HCT116 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C4OVczKGh? MY\JR|UxRTFwN9MxNE41KM7:TR?= MWiyOFE4OjB4MR?=
HepG2 MX7GeY5kfGmxbjDBd5NigQ>? NEnPcZYxNjVxMTFOwG0> NWPtO3hiOjRiaB?= NYX3XI1uTE2VTx?= M3X0V5VxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M4HyWlI1OTR4OEe0
LS174T MWjGeY5kfGmxbjDBd5NigQ>? NEPOemQxNjVxMTFOwG0> NGnNeZgzPCCq Mmf1SG1UVw>? Ml3kcIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO= MnLLNlQyPDZ6N{S=
HepG2 MnTpRZBweHSxc3nzJGF{e2G7 NXjOXHNlOS9zMD:xNFAh|ryP MnW2O{Bl NXTaWVJJTE2VTx?= MkTZbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYiyOFE1Pjh5NB?=
LS174T NETBUVZCeG:ydH;zbZMhSXO|YYm= MXGxM|ExNzFyMDFOwG0> MYi3JIQ> M2O1TGROW09? NW[xPJZQcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUTSd4RJOjRzNE[4O|Q>
QBC-939 NY\WTWs6SXCxcITvd4l{KEG|c3H5 M4TmXlEwOTBxMUCwJO69VQ>? Mn2yO{Bl MYnEUXNQ MUDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mn3UNlQyPDZ6N{S=
U251 NWnaZVFMSXCxcITvd4l{KEG|c3H5 M3XjUVEwOTBxMUCwJO69VQ>? NGHBPIY4KGR? M3T5Z2ROW09? MXzpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFXuVIczPDF2Nki3OC=>
HL-60 M2\jeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T4fVEh|ryP NVn4PZhvPDhiaB?= MljrbY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? Mki2NlQxODB|MkS=
MDA‑MB‑453 NIjve4VHfW6ldHnvckBCe3OjeR?= NHPXR5cxNjJxMTFOwG0> MW[3NkBp MknpZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NFW5fokzOzh2NEKyPC=>
HCC1569 MWXGeY5kfGmxbjDBd5NigQ>? NFLBPZoxNjJxMTFOwG0> NFLSU3Q4OiCq M2PxO4NifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> M33vSFI{QDR2MkK4
BT‑474 MV3GeY5kfGmxbjDBd5NigQ>? Mkf2NE4zNzFizszN NVrybZRoPzJiaB?= NWjrSFdr[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh M{\yelI{QDR2MkK4
AGS NXj4VJB2SXCxcITvd4l{KEG|c3H5 MmG4OU8yOC9{MD:1NEDPxE1? NXLTUGZIPDkEoHlCpC=> NYDyXoxzTE2VTx?= MYnpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NVXneGk{OjN3OEK3PFQ>
A549 NUXB[5p5SXCxcITvd4l{KEG|c3H5 M4K5clUwOTBxMkCvOVAh|ryP M4fi[lQ5yqCqwrC= NF3nOHJFVVOR M1jpXIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh MlP2NlM2QDJ5OES=
AGS  NG[yOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvEOU8yOC9{MD:1NEDPxE1? MYO0POKhcMLi NVTjboZiTE2VTx?= NEjQfHZqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA> MmS5NlM2QDJ5OES=
Kasumi-1 MofWRZBweHSxc3nzJGF{e2G7 MYmwMlUh|ryP M4PQSFQ5yqCqwrC= NYnaPIxm\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> M2fhWlI{PDl|M{S4
OCI-AML3 MVLBdI9xfG:|aYOgRZN{[Xl? MUGyMlUh|ryP MnfzOFjDqGkEoB?= NEW2OHNl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NUDtelFVOjN2OUOzOFg>
MV4-11 MnzRRZBweHSxc3nzJGF{e2G7 M3z6XFIvPSEQvF2= MnjDOFjDqGkEoB?= M{LXUIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NFH0N5QzOzR7M{O0PC=>
NK  MWPDfZRwfG:6aYT5JGF{e2G7 M1fmR|AvODJvMkCg{txO M4rIblUh\A>? MnjW[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26|ZTDjeZJ3\Q>? MonZNlM{OjhyOEi=
NK  NFHyUm1CeG:ydH;zbZMhSXO|YYm= NIGyOWUxNjB{LUKwJO69VQ>? Mn\iOUBl NYfH[JJQ\GWlcnXhd4UhVktiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJkh[XNidHjlJINwdmOnboTyZZRqd25iaX7jdoVie2Wm NULmXnd[OjN|MkiwPFg>
NK  MV3GeY5kfGmxbjDBd5NigQ>? M4C1c|AvODFvMkCg{txO NX3DVW1DPSCm MX3jZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl NUX2VoJvOjN|MkiwPFg>
MOLT4/DNR NXjR[Id3TnWwY4Tpc44hSXO|YYm= NYjmcXZNPSEQvF2= MYC0JIQ> NFS3Vm9z\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? MWSyN|A3ODV5MB?=
Jurkat/DOX M1r3c2Z2dmO2aX;uJGF{e2G7 MU[1JO69VQ>? MUK0JIQ> Ml;2doVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> MoLQNlMxPjB3N{C=
MOLT4/DNR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLkTpVMPSEQvF2= NV3mWpRMPCCm MnHadoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= MYeyN|A3ODV5MB?=
Jurkat/DOX NF3JXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvKNIpjPSEQvF2= NHnUWWY1KGR? M3PCZ5Jm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= NWLsS5BkOjNyNkC1O|A>
ccRCC  NVHMPI5mSXCxcITvd4l{KEG|c3H5 NF;NRoIxNjBzLUGw{txO M1XLXVczKGh? NXTidnhoTE2VTx?= NFjpfnVp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w M{LmSVIzQDJ4NE[3
TNBC  NXPjSWtpSXCxcITvd4l{KEG|c3H5 M1PCdFAvODFvMUFOwG0> M3PudVczKGh? NWDWPFhITE2VTx?= NELhUIJp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w MYmyNlgzPjR4Nx?=
A498 NVfK[WQ5SXCxcITvd4l{KEG|c3H5 NG\JfIcxNjBzLUGw{txO MlHwO|IhcA>? MlqxSG1UVw>? NGroSnFqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MlviNlI5OjZ2Nke=
KIJ265T MnOzRZBweHSxc3nzJGF{e2G7 MlntNE4xOS1zMN88US=> M1vLd|czKGh? M{TYWmROW09? M3m3dYlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> NVq4NpN3OjJ6Mk[0Olc>
MDA-231 MlS1RZBweHSxc3nzJGF{e2G7 MX6wMlAyNTFyzszN NITuT4k4OiCq MUfEUXNQ MYjpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu Mm\KNlI5OjZ2Nke=
BT-20 M4DST2Fxd3C2b4Ppd{BCe3OjeR?= MoL2NE4xOS1zMN88US=> NF7JSFU4OiCq NHf2SGRFVVOR NXzRTVJEcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NELkPJkzOjh{NkS2Oy=>
U937 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXafJI2NTJyIN88US=> M{DHVlI1NzR6L{eyJIg> NYLjO3FwcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NUGyXHZ5OjJ5NkewNlE>
HL60 NXv3bphqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnPOU0zOCEQvF2= NISxUYUzPC92OD:3NkBp MljjbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NXHOd|Q3OjJ5NkewNlE>
U937 NYT5bWcxSXCxcITvd4l{KEG|c3H5 NYm3UlQ3OTVizszN NV7jOlJ2OjRxNEivO|IhcA>? Ml3IbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVWyNoZsOjJ5NkewNlE>
HL60 MnfQRZBweHSxc3nzJGF{e2G7 NVzkTY46OTVizszN MnqyNlQwPDhxN{KgbC=> MYDpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFH6V4YzOjd4N{CyNS=>
LS411N  M4HBPWFxd3C2b4Ppd{BCe3OjeR?= MX[wMlUh|ryP M3rpOFczKGh? NHLSWXZqdmO{ZXHz[ZMhTmG|IH3SUmEhdGW4ZXy= M3TLUFIzPDZzNkm1
MDA-MB-231 M1j1eGFxd3C2b4Ppd{BCe3OjeR?= MlPCNVAh|ryP MkXPOFghcA>? M3TZeJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYOyNVg5PzZ7Nx?=
MCF-7  NF\Pb2pCeG:ydH;zbZMhSXO|YYm= MVSxNEDPxE1? MmDpOFghcA>? NVfM[45zemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mn3XNlE5QDd4OUe=
A375 M1nPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWwMlUh|ryP NYKyboFSOS93L{ig[C=> M3\4WolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NHizTFMzOTd7Nk[yNi=>
SKMEL1 NFHvdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHvNE42KM7:TR?= NH\RfXYyNzVxODDk NWXYUGlicW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NWHCb5BDOjF5OU[2NlI>
SKMEL3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r1UlAvPSEQvF2= NHe4WXgyNzVxODDk MoXKbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MnW0NlE4QTZ4MkK=
SKMEL28 MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrWXo0xNjVizszN MVGxM|UwQCCm MVrpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NXzYNmJvOjF5OU[2NlI>
MeWo MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLxV4oyOC53IN88US=> NWXMU3lIOS93L{ig[C=> M{TCeYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MkjJNlE4QTZ4MkK=
B16 NHPCbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7McJZVOC53IN88US=> NXvQcnRQOS93L{ig[C=> NH33fo9qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MXSyNVc6PjZ{Mh?=
Ly 1 M2SxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2job|I1KGh? NGfSSmlKSzVyPUeuN{DPxE1? NHzJeVEzOTd5MkC0PS=>
Ly 7 M2\0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4POfFI1KGh? M1XWU2lEPTB;MUCuO{DPxE1? MlzONlE4PzJyNEm=
Su-DHL6 M2fs[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jJWFI1KGh? M4H2e2lEPTExvK6yNEDPxE1? NYHCNWJXOjF5N{KwOFk>
Ly 10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nDXVI1KGh? M1j3XGlEPTExvK6yNEDPxE1? NUDPR2dHOjF5N{KwOFk>
RIVA NEPvVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOyOEBp NU\NW2pjUUN3MP-8olIxKM7:TR?= MWOyNVc4OjB2OR?=
Su-DHL2 M4LRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nNO|I1KGh? MoHTTWM2OO,:nkKwJO69VQ>? NWH6cWI{OjF5N{KwOFk>
Ly 1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvxXnV7PDhiaB?= MoXFTWM2OD1yLkO0JO69VQ>? MWOyNVc4OjB2OR?=
Ly 7 NFTRcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnrOFghcA>? MmX1TWM2OD1yLkCyOUDPxE1? NULFVZh4OjF5N{KwOFk>
Su-DHL6 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILOe5g1QCCq M{PFUmlEPTExvK6yNEDPxE1? MY[yNVc4OjB2OR?=
Ly 10 NU\D[odqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC0PEBp M1qwT2lEPTB;MT64JO69VQ>? MorrNlE4PzJyNEm=
RIVA NVXNc5I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX5OFghcA>? M1fzcGlEPTExvK6yNEDPxE1? NYG1NlZDOjF5N{KwOFk>
Su-DHL2 NVrlbYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;vOFghcA>? MmHGTWM2OD1zNz60JO69VQ>? MXSyNVc4OjB2OR?=
Ly 1 M1;Lbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLDNHlJPzJiaB?= NUHKeXVbUUN3ME2wMlAyKM7:TR?= MUCyNVc4OjB2OR?=
Ly 7 NHvRT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTreIY4OiCq MmO3TWM2OD1yLkCxPEDPxE1? Mmi5NlE4PzJyNEm=
Su-DHL6 MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXsO|IhcA>? MYDJR|UxRTFwNjFOwG0> M1HQeFIyPzd{MES5
Ly 10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLaO5c4OiCq NUDFXI9uUUN3ME2xMlIh|ryP NYH6R5NTOjF5N{KwOFk>
RIVA M2LFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XmcFczKGh? Mn;CTWM2OO,:nkKwJO69VQ>? MX[yNVc4OjB2OR?=
Su-DHL2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXW3NkBp M1jZ[GlEPTB;MUGuNkDPxE1? M{\MOVIyPzd{MES5

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
- Collapse

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
- Collapse
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04086238 Completed Drug: Decitabine Healthy EpiDestiny Inc. October 8 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03875287 Recruiting Drug: Decitabine|Drug: Cedazuridine Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals Inc. April 17 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID